Genetic variation of stress hormone receptor may affect vulnerability to major depression

Link between schizophrenia and individual variations in GABA and glutamate transmission grows stronger

New evidence suggests that schizophrenics possess mutations affecting genes associated with GABA, a neurotransmitter that relaxes nervous system activity. The analysis, which included the largest sample size to date -- comparing the genes of 11,500 people with schizophrenia to 16,500 people without the disorder -- also replicated and expanded upon previous research implicating schizophrenia with genes related to the excitatory neurotransmitter glutamate. Neuroscientists Andrew Pocklington, Michael O'Donovan, and Michael Owen of Cardiff University led the study, which did not find significant differences between the two groups in genes unrelated to the central nervous system.

The authors believe that the risk of schizophrenia depends on the total burden of mutations and that no single gene can be blamed for acquiring the disorder. Mutations in genes that can disrupt GABA and glutamate signaling, however, appear more likely than others to be associated with schizophrenia among the most clearly involved.

'Perturbation of these processes is likely to have a widespread impact on brain function, and only a subset of genetic lesions within these systems may be compatible with a schizophrenia phenotype,' write the authors. 'The identification of the mechanisms by which disruption of these processes by genetic mutation leads to psychopathology will doubtless require experimental studies in model systems of high construct validity.'

An argument to pinpoint the GABA receptor as a drug target for neurodevelopmental disorders

Thousands of genes have been linked to neurodevelopmental disorders, including autism and epilepsy, complicating attempts to find any one particular drug or therapy that could help patients. One lead from gene sequencing studies is the revelation that many of the genes associated with these disorders converge on a limited number of functional pathways.

Geneticists Sien Braat and R. Frank Kooy of the University of Antwerp argue that one intriguing commonality between neurodevelopmental disorders is a disturbance in the function of GABA signaling, responsible for preventing too much brain activity. Based on research using drugs targeting GABA signaling to treat fragile X syndrome in animal models, the researchers believe that clinical trials using these drugs (already approved for human use) would be worth pursuing for a wider range of neurodevelopmental disorders.

'Due to the genetic heterogeneity observed, targeted treatment aimed at interference with pathways commonly disturbed in multiple disorders might be the only realistic option,' write the authors. 'Results of preclinical trials in several [neurodevelopmental] disorders have shown encouraging results and raised hopes for treatment in patients.'